Management

John Melo President & Chief Executive Officer
Image of John Melo
With Amyris since 2007

John Melo has nearly three decades of combined experience as an entrepreneur and thought leader in the global fuels industry and technology innovation. Mr. Melo has served as our Chief Executive Officer and a director since January 2007 and as our President since June 2008. Before joining Amyris, Mr. Melo served in various senior executive positions at BP Plc (formerly British Petroleum), one of the world’s largest energy firms, from 1997 to 2006, most recently as President of U.S. Fuels Operations from 2004 until December 2006, and previously as Chief Information Officer of the refining and marketing segment from 2001 to 2003, Senior Advisor for e-business strategy to Lord Browne, BP Chief Executive, from 2000 to 2001, and Director of Global Brand Development from 1999 to 2000. Before joining BP, Mr. Melo was with Ernst & Young, an accounting firm, from 1996 to 1997, and a member of the management teams of several startup companies, including Computer Aided Services, a management systems integration company, and Alldata Corporation, a provider of automobile repair software to the automotive service industry. Mr. Melo currently serves on the board of directors of U.S. Venture, Inc. and Renmatix, Inc., and also serves as Vice Chairman of the board of directors of BayBio. Mr. Melo was formerly an appointed member to the U.S. section of the U.S.-Brazil CEO Forum. 

Download Photo


Recent Stock Transactions by John Melo
Date Type Shares Traded Price Range
May 15, 2014 Sell 172,186 3.02
May 5, 2014 Acquisition (Non Open Market) 300,000 n/a
Apr 1, 2014 Disposition (Non Open Market) 126,677 4.44
Jan 1, 2014 Disposition (Non Open Market) 3,363 4.71
Jun 3, 2013 Acquisition (Non Open Market) 239,000 n/a
May 24, 2013 Sell 24,402 2.85
Apr 1, 2013 Disposition (Non Open Market) 6,113 3.06
Jan 2, 2013 Disposition (Non Open Market) 3,364 3.20
Aug 31, 2012 Sell 553,730 3.70
Aug 31, 2012 Sell 115,000 3.70
Aug 31, 2012 Option Execute 553,730 0.28
Aug 31, 2012 Option Execute 115,000 0.28
May 15, 2012 Acquisition (Non Open Market) 3,273 1.53
Apr 9, 2012 Acquisition (Non Open Market) 250,000 n/a
Jan 3, 2012 Disposition (Non Open Market) 3,225 12.27
Oct 10, 2011 Automatic Sell 20,000 17.22
Oct 10, 2011 Option Execute 20,000 0.28
Aug 10, 2011 Automatic Sell 27,500 20.02 - 20.67
Aug 10, 2011 Option Execute 27,500 0.28
Aug 9, 2011 Automatic Sell 23,800 19.66 - 20.44
Aug 9, 2011 Option Execute 23,800 0.28
Aug 8, 2011 Automatic Sell 18,500 20.04 - 20.55
Aug 8, 2011 Option Execute 18,500 0.28
Jul 8, 2011 Automatic Sell 6,000 28.28
Jul 8, 2011 Option Execute 6,000 0.28
Jul 7, 2011 Automatic Sell 7,000 27.97
Jul 7, 2011 Option Execute 7,000 0.28
Jul 6, 2011 Automatic Sell 4,500 28.21
Jul 6, 2011 Option Execute 4,500 0.28
Jul 5, 2011 Automatic Sell 8,000 27.89
Jul 5, 2011 Option Execute 8,000 0.28
Jul 1, 2011 Automatic Sell 19,970 28.05
Jul 1, 2011 Option Execute 19,970 0.28
Jun 30, 2011 Automatic Sell 11,900 28.19
Jun 30, 2011 Option Execute 11,900 0.28
Apr 15, 2011 Acquisition (Non Open Market) 23,000 n/a
Mar 29, 2011 Automatic Sell 53,100 27.99
Mar 29, 2011 Option Execute 53,100 0.28
Mar 28, 2011 Automatic Sell 56,000 27.10
Mar 28, 2011 Option Execute 56,000 0.28
Joel Cherry Ph.D. President, Research & Development
Image of Joel Cherry Ph.D.
With Amyris since 2008

Joel Cherry leads Amyris research and development, including various ongoing collaborations. Prior to joining Amyris, Dr. Cherry was Senior Director of bioenergy biotechnology at Novozymes. During his tenure at Novozymes, he was a member of the R&D management team specializing in protein engineering and directed evolution technologies. He was also principal investigator and director of the BioEnergy Project, an effort funded by the U.S. Department of Energy to reduce the cost of enzymes used in converting biomass to sugar. This work was awarded an R&D 100 Award, Scientific American Top 50 Award, and a Frost and Sullivan Emerging Technology Award. Dr. Cherry is an inventor on more than 20 issued patents, author of three book chapters and more than 30 scientific publications, and an invited speaker at numerous international conferences on biofuels. He received his B.A. from Carleton College in chemistry, a Ph. D. in biochemistry from the University of New Hampshire.

Download Photo


Recent Stock Transactions by Joel Cherry Ph.D.
Date Type Shares Traded Price Range
May 5, 2014 Acquisition (Non Open Market) 92,000 n/a
Apr 1, 2014 Disposition (Non Open Market) 58,373 4.44
Jan 1, 2014 Disposition (Non Open Market) 1,462 4.71
Jun 3, 2013 Acquisition (Non Open Market) 111,000 n/a
Apr 1, 2013 Disposition (Non Open Market) 6,724 3.06
May 15, 2012 Acquisition (Non Open Market) 1,103 1.53
Apr 9, 2012 Acquisition (Non Open Market) 155,000 n/a
Jan 3, 2012 Disposition (Non Open Market) 1,402 12.27
Jan 3, 2012 Disposition (Non Open Market) 1,462 3.20
Sep 26, 2011 Automatic Sell 4,500 19.47
Sep 26, 2011 Option Execute 4,500 4.31
Aug 29, 2011 Automatic Sell 500 19.89
Aug 29, 2011 Option Execute 500 4.31
Aug 26, 2011 Automatic Sell 4,000 18.35
Aug 26, 2011 Option Execute 4,000 4.31
Aug 8, 2011 Automatic Sell 4,500 20.05
Aug 8, 2011 Option Execute 4,500 4.31
Jun 27, 2011 Automatic Sell 5,000 29.75 - 30.37
Jun 27, 2011 Option Execute 5,000 4.31
Jun 24, 2011 Automatic Sell 4,397 29.90
Jun 24, 2011 Option Execute 4,397 4.31
Jun 21, 2011 Automatic Sell 3,068 29.91
Jun 21, 2011 Option Execute 3,068 4.31
May 27, 2011 Automatic Sell 914 29.90
May 27, 2011 Option Execute 914 4.31
May 26, 2011 Automatic Sell 6,621 28.64 - 29.90
May 26, 2011 Option Execute 6,621 4.31
May 9, 2011 Automatic Sell 5,000 25.01
May 9, 2011 Option Execute 5,000 4.31
Apr 15, 2011 Acquisition (Non Open Market) 10,000 n/a
Mar 29, 2011 Automatic Sell 3,000 28.08
Mar 29, 2011 Option Execute 3,000 4.31
Mar 28, 2011 Automatic Sell 5,000 27.14
Mar 28, 2011 Option Execute 5,000 4.31
Paulo Diniz Chief Financial Officer
Image of Paulo Diniz
With Amyris since 2011

Paulo Diniz is Amyris's interim Chief Financial Officer since December 2013. Previously he led Amyris operations in Brazil. Prior to joining Amyris in March 2011, Mr. Diniz served as Chief Financial Officer of Bunge Brasil S.A., a wholly owned subsidiary of Bunge Ltd., an agribusiness and food company, from April 2009 to November 2010. From 2003 to April 2009, Mr. Diniz was Chief Financial Officer and a member of the board of directors of Cosan S.A., a renewable energy company. He received a Master of Business Administration degree from International Institute for Management Development (IMD) in Switzerland, a B. of Sc. degree in Production Engineering from the University of São Paulo (USP) in Brazil, and participated in a post graduate program in human resources at INSEAD in France.

Download Photo


Recent Stock Transactions by Paulo Diniz
Date Type Shares Traded Price Range
May 5, 2014 Acquisition (Non Open Market) 47,000 n/a
Dec 16, 2013 Acquisition (Non Open Market) 50,000 n/a
Jun 3, 2013 Acquisition (Non Open Market) 40,000 n/a
Apr 9, 2012 Acquisition (Non Open Market) 50,000 n/a
Apr 15, 2011 Acquisition (Non Open Market) 40,000 n/a
Nicholas Khadder General Counsel & Corporate Secretary
Image of Nicholas Khadder
With Amyris, Inc. since 2010

Nick Khadder is Amyris's General Counsel and Corporate Secretary. He joined Amyris in October 2010 as Assistant General Counsel. Prior to joining Amyris, Mr. Khadder served as Corporate Counsel at LeapFrog Enterprises and at Robert Half International, and as Assistant General Counsel at Protiviti.  Before going in-house, he was an associate at Fenwick & West.  Mr. Khadder has a J.D. from U.C. Berkeley’s Boalt Hall School of Law, and an A.B. in English from U.C. Berkeley.

Download Photo

 

Recent Stock Transactions by Nicholas Khadder
Date Type Shares Traded Price Range
Oct 1, 2014 Disposition (Non Open Market) 8,330 3.70
May 5, 2014 Acquisition (Non Open Market) 46,000 n/a
Apr 9, 2014 Disposition (Non Open Market) 1,227 3.96
Apr 1, 2014 Disposition (Non Open Market) 4,890 4.44
Feb 13, 2014 Statement of Ownership 0 n/a
Charles Kraft Vice President, Global Manufacturing & Process Development
Image of Charles Kraft
With Amyris since 2012

Chuck Kraft leads Amyris global manufacturing and process development operations. Mr. Kraft has three decades of experience in specialty fermentation. Prior to joining Amyris, he was Vice President of Operations, and earlier Vice President of Engineering, at DuPont Tate and Lyle BioProducts, a joint venture producing 1, 3-propanediol (Bio-PDO™) via fermentation of plant-based sugars. Previously, for nearly two decades, he held a number of operational positions at Tate & Lyle's citric acid production facility in the United States. He holds MBA and B.S. Degrees from the University of Dayton, Ohio.

Download Photo


Zanna McFerson Chief Business Officer
Image of Zanna McFerson
With Amyris since 2013

Zanna McFerson leads business development, commercial and product line activities.  Prior to joining Amyris, McFerson was Vice President of Cargill and Business Director of Truvia®, the leading global natural sugar substitute business she helped create over the past decade. In this position, she directed an extensive global team with resources across research and development, agronomy, supply chain, scientific and regulatory affairs, sales and marketing.  She has played a leading role in fundamentally changing the sugar substitute industry by creating consumer demand for a novel sweetener and in forming a trade group, The International Stevia Council, where she most recently served as President.  During her tenure, the business received numerous awards in the area of technology, public relations and marketing while lauded for its sustainability efforts.  In March 2014, McFerson was appointed to serve on the Board of Directors for The Real Stevia Company, Granular AB (Sweden).   A native of Finland, McFerson joined Cargill in 1990 as a commodity trader and held various roles in sales, business management, and new product development at Cargill.  She received a bachelor’s degree in Economics from the University of Illinois and a Masters of Business Administration from the University of Iowa.

Download Photo


Recent Stock Transactions by Zanna McFerson
Date Type Shares Traded Price Range
May 5, 2014 Acquisition (Non Open Market) 42,000 n/a
Mar 4, 2014 Disposition (Non Open Market) 30,759 5.05
Mar 11, 2013 Acquisition (Non Open Market) 130,000 n/a
Mar 4, 2013 Statement of Ownership 0 n/a
Jack Newman Ph.D. Chief Science Officer
Image of Jack Newman Ph.D.
With Amyris since 2003
Jack Newman co-founded Amyris with four post-docs and their professor at the University of California, Berkeley in 2003. Dr. Newman is an inventor of the original patented technology underpinning the Amyris production platform, work that led to a grant he co-authored and funded by the Bill and Melinda Gates Foundation to produce a cure for malaria using synthetic biology. At Amyris, Dr. Newman has lead a research group of over 100 scientists and engineers and currently focuses on innovation in microbial engineering. He has over two decades of research experience in molecular biology, microbial physiology and genetics. He received his doctorate from the University of Wisconsin, Madison, and a B.A. in molecular and cellular biology from the University of California, Berkeley. Dr. Newman current serves on the board of directors of the Biobricks Foundation, a public benefit company with a mission to “ensure that the engineering of biology is conducted in an open and ethical manner to benefit all people and the planet.” He also chairs the Board of Directors of zagaya, a public benefit company he co-founded “to improve the human condition through the targeted application of science-based technology and education.”

Download Photo


Karen Rohde Chief Human Resources Officer
Image of Karen Rohde
With Amyris, Inc. since 2013

Karen Rohde is Amyris's Chief Human Resources Officer. Previously, Ms. Rohde was Senior Vice President Human Resources for Hitachi Global Storage Technologies, Inc. (HGST), where she helped drive the company’s turnaround by building a customer-focused, high-performance culture that promoted global alignment, agility and collaboration across its 45,000 employee organization. Prior to HGST, she was Senior Vice President Human Resources & Chief Talent Officer for Sun Microsystems, Inc.  During her 13-year tenure at Sun, Rohde designed and implemented competitive, integrated talent systems and supported multiple acquisitions.  Rohde began her career in Finance at Mobil Oil Corporation.  Rohde has an MBA from the Haas Business School at University of California at Berkeley and a BA in English from the University of California at Irvine. 


Joel Velasco Senior Vice President
Image of Joel Velasco
With Amyris since 2011

Joel Velasco is Senior Vice President at Amyris, an integrated renewable products company focused on providing sustainable alternatives to a broad range of petroleum-sourced products. He brings more than 10 years of experience in international public policy, with a focus on U.S.-Brazil business relations. Prior to joining Amyris, he was Chief Representative in North America for the Brazilian Sugarcane Industry Association (UNICA), where he led UNICA’s efforts to expand international biofuel and sugar markets. He remains an advisor to UNICA's board. Prior to joining UNICA, Velasco was managing director of Albright Stonebridge, an international strategic advisory firm based in Washington, D.C. and previously served as senior advisor to the U.S. Ambassador to Brazil and as a personal aide to Vice President Al Gore in the White House. Mr. Velasco received an M.A. from the Georgetown University School of Foreign Service, focusing his studies on the political-economy of the Southern Cone, and a B.A. in Political Science from Hampden-Sydney College in Virginia. In addition to his advisory role at UNICA, Mr. Velasco is a member of the board of the Advanced Biofuels Association, the Brazil Institute at the Wilson Center, and staff representative on the U.S.-Brazil CEO Forum.

Download Photo


Stock transaction information provided by EDGAR Online. Amyris makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.